Q1 Earnings Estimate for Repligen Issued By Leerink Partnrs

Repligen Co. (NASDAQ:RGEN) – Stock analysts at Leerink Partnrs decreased their Q1 2025 earnings per share (EPS) estimates for shares of Repligen in a note issued to investors on Thursday, February 20th. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will post earnings per share of $0.35 for the quarter, down from their prior estimate of $0.39. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen’s Q4 2025 earnings at $0.51 EPS, FY2025 earnings at $1.72 EPS and FY2026 earnings at $2.33 EPS.

A number of other research firms have also recently issued reports on RGEN. Canaccord Genuity Group increased their price objective on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Finally, TD Cowen initiated coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average target price of $181.00.

Repligen Price Performance

RGEN stock opened at $161.47 on Monday. The stock has a market capitalization of $9.05 billion, a PE ratio of -316.61, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The company’s 50-day moving average is $155.30 and its 200-day moving average is $148.57. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen has a 1 year low of $113.50 and a 1 year high of $203.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in RGEN. CWM LLC lifted its holdings in shares of Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 114 shares during the last quarter. Creative Planning increased its position in shares of Repligen by 32.6% in the third quarter. Creative Planning now owns 5,123 shares of the biotechnology company’s stock valued at $762,000 after acquiring an additional 1,259 shares during the period. Blue Trust Inc. increased its position in shares of Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the period. Raymond James & Associates increased its position in shares of Repligen by 49.3% during the third quarter. Raymond James & Associates now owns 82,277 shares of the biotechnology company’s stock valued at $12,244,000 after buying an additional 27,158 shares during the period. Finally, Greenleaf Trust purchased a new stake in Repligen in the third quarter worth about $226,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.